Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda

被引:11
|
作者
Tukei, Vincent J. [1 ]
Murungi, Miriam [1 ]
Asiimwe, Alice R. [1 ]
Migisha, Daniella [1 ]
Maganda, Albert [1 ]
Bakeera-Kitaka, Sabrina [3 ]
Kalyesubula, Israel [1 ]
Musoke, Philippa [2 ,3 ]
Kekitiinwa, Adeodata [1 ]
机构
[1] Mulago Hosp, Baylor Coll Med, Bristol Myers Squibb Childrens Clin Ctr Excellenc, Kampala, Uganda
[2] Makerere Univ Johns Hopkins Univ Res Collaborat C, Kampala, Uganda
[3] Makerere Univ, Coll Hlth Sci, Dept Pediat & Child Hlth, Kampala, Uganda
来源
BMC PEDIATRICS | 2013年 / 13卷
关键词
Infant; HIV; Antiretroviral therapy; Mortality; Malnutrition; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CHILDREN; PEDIATRIC HIV; RISK-FACTORS; MORTALITY; INITIATION; OUTCOMES; YOUNG; URBAN; ART;
D O I
10.1186/1471-2431-13-42
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Antiretroviral therapy (ART) is known to save lives. Among HIV-infected infants living in resource constrained settings, the short and long term benefits of ART are only partially known. This study was designed to determine the virologic, immunologic and clinical outcomes of antiretroviral therapy in a cohort of HIV-infected infants receiving care from an outpatient clinic in Kampala, Uganda. Methods: A prospective cohort of HIV-infected infants receiving treatment at the Baylor-Uganda clinic was analyzed. Patients were diagnosed, enrolled and followed up at the clinic. HIV viral load, CD4 cell counts and clinical progress were assessed during follow-up. Descriptive statistical analysis and logistic regression modeling to determine predictors of treatment success were conducted. Results: Of 91 HIV-infected infants enrolled into the cohort, 53 (58.2%) infants were female; 43 (47.3%) were 6 months of age or younger, and 50 (55.6%) had advanced HIV/AIDS disease (Clinical stage 3 or 4). Eighty four infants started ART and 78 (92.9%) completed 6 months of treatments. Fifty six (71.8%) infants attained virologic suppression by month-6 of ART, and at month-12 of ART, the cumulative probability of attaining viral suppression was 83.1%. None of the baseline infant factors (age, sex, WHO stage, CD4 cell percent, weight for age, or height for age z-score) predicted treatment success. There was an increase in CD4 cells from a baseline mean of 23% to 30% at month-6 of treatment (p<0.001) and by month-24 of ART, the mean CD4 percent was 36%. A total of 7 patients died while on ART and another 7 experienced adverse events that were related to treatment. Conclusion: Our results show that, even among very young patients from resource constrained settings, ART dramatically suppresses HIV replication, allows immune recovery and clinical improvement, and is safe. However, baseline characteristics do not predict recovery in this age group.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-iInfected women
    Vaamonde, CM
    Hoover, DR
    Anastos, K
    Tan, T
    Shi, Q
    Gao, W
    Kovacs, A
    Cohen, M
    DeHovitz, J
    Glesby, MJ
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (03) : 222 - 231
  • [32] Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands
    Nellen, JF
    Wit, FW
    de Wolf, F
    Jurriaans, S
    Lange, JM
    Prins, JM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (04) : 943 - 950
  • [33] Clinical Outcome of HIV Infected Patients Receiving Antiretroviral Therapy with Immunologic-Virologic Discordance (2012-2016)
    Abbasian, Ladan
    Ashtiani, Masoumeh Farrokh
    Najafi, Zeinab
    Seyedalinaghi, SeyedAhmad
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2019, 7 (01): : 9 - 14
  • [34] Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
    Reynolds, Steven J.
    Sendigire, Hakim
    Newell, Kevin
    Castelnuovo, Barbara
    Nankya, Immaculate
    Kamya, Moses
    Quinn, Thomas C.
    Manabe, Yukari C.
    Kambugu, Andrew
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 : 33 - 33
  • [35] Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
    Reynolds, Steven J.
    Sendagire, Hakim
    Newell, Kevin
    Castelnuovo, Barbara
    Nankya, Immaculate
    Kamya, Moses
    Quinn, Thomas C.
    Manabe, Yukari C.
    Kambugu, Andrew
    BMC INFECTIOUS DISEASES, 2012, 12
  • [36] Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression
    Moore, David M.
    Harris, Ross
    Lima, Viviane
    Hogg, Bob
    May, Margaret
    Yip, Benita
    Justice, Amy
    Mocroft, Amanda
    Reiss, Peter
    Lampe, Fiona
    Chene, Genevieve
    Costagliola, Dominique
    Elzi, Luigia
    Mugavero, Michael J.
    Monforte, Antonella D'Arminio
    Sabin, Caroline
    Podzamczer, Daniel
    Faetkenheuer, Gerd
    Staszewski, Schlomo
    Gill, John
    Sterne, Jonathan A. C.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (03) : 357 - 363
  • [37] Frequency and Predictors for Late Start of Antiretroviral Therapy in Primary Care Clinics, Kampala, Uganda
    Sendagire, Ibrahim
    Cobelens, Frank
    Kambugu, Andrew
    Konde-Lule, Joseph
    van der Loeff, Maarten Schim
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (03) : E33 - E39
  • [38] Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda
    Victor Ssempijja
    Gertrude Nakigozi
    Larry Chang
    Ron Gray
    Maria Wawer
    Anthony Ndyanabo
    Jingo Kasule
    David Serwadda
    Barbara Castelnuovo
    Anja van’t Hoog
    Steven James Reynolds
    BMC Infectious Diseases, 17
  • [39] Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda
    Ssempijja, Victor
    Nakigozi, Gertrude
    Chang, Larry
    Gray, Ron
    Wawer, Maria
    Ndyanabo, Anthony
    Kasule, Jingo
    Serwadda, David
    Castelnuovo, Barbara
    van't Hoog, Anja
    Reynolds, Steven James
    BMC INFECTIOUS DISEASES, 2017, 17
  • [40] Rate and predictors of optimal virologic response to antiretroviral therapy in Colombia
    DiazGranados, Carlos A.
    Silva, Alfonso
    Bermudez, Adriana
    Roncancio, Diana
    Diruggiero, Pierina
    Mantilla, Monica
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (06) : 531 - 535